☰

John M. Hatcher, Ph.D. - Publications

Affiliations: 
2011 Chemistry Duke University, Durham, NC 
 2012- Cancer Biology Dana-Farber Cancer Institute/Harvard Medical School 
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Hatcher JM, Zwirek M, Sarhan AR, Vatsan PS, Tonelli F, Alessi DR, Davies P, Gray NS. Development of a Highly Potent and Selective Degrader of LRRK2. Bioorganic & Medicinal Chemistry Letters. 129449. PMID 37591317 DOI: 10.1016/j.bmcl.2023.129449  0.631
2023 Gao Y, Jiang B, Kim H, Berberich MJ, Che J, Donovan KA, Hatcher JM, Huerta F, Kwiatkowski NP, Liu Y, Liuni PP, Metivier RJ, Murali VK, Nowak RP, Zhang T, et al. Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. Journal of Medicinal Chemistry. PMID 37036171 DOI: 10.1021/acs.jmedchem.2c01864  0.801
2022 Chow HY, Karchugina S, Groendyke BJ, Toenjes S, Hatcher J, Donovan KA, Fischer ES, Abalakov G, Faezov B, Dunbrack R, Gray NS, Chernoff J. Development and Utility of a PAK1-Selective Degrader. Journal of Medicinal Chemistry. 65: 15627-15641. PMID 36416208 DOI: 10.1021/acs.jmedchem.2c00756  0.689
2022 Malone CF, Kim M, Alexe G, Engel K, Forman AB, Robichaud A, Saur Conway A, Goodale A, Meyer A, Khalid D, Thayakumar A, Hatcher JM, Gray NS, Piccioni F, Stegmaier K. Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors. Cancer Research. PMID 36398965 DOI: 10.1158/0008-5472.CAN-21-4309  0.604
2022 Powell CE, Hatcher JM, Jiang J, Vatsan PS, Che J, Gray NS. Selective Macrocyclic Inhibitors of DYRK1A/B. Acs Medicinal Chemistry Letters. 13: 577-585. PMID 35450378 DOI: 10.1021/acsmedchemlett.1c00630  0.794
2022 Son J, Jang J, Beyett TS, Eum Y, Haikala HM, Verano A, Lin M, Hatcher JM, Kwiatkowski NP, Eser PÖ, Poitras MJ, Wang S, Xu M, Gokhale PC, Cameron MD, et al. A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer. Cancer Research. PMID 35149586 DOI: 10.1158/0008-5472.CAN-21-2693  0.769
2021 Hatcher JM, Vatsan PS, Wang E, Jiang J, Gray NS. Development of Highly Potent and Selective Pyrazolopyridine Inhibitor of CDK8/19. Acs Medicinal Chemistry Letters. 12: 1689-1693. PMID 34795857 DOI: 10.1021/acsmedchemlett.1c00300  0.753
2020 Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, ... ... Hatcher J, et al. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. PMID 33275901 DOI: 10.1016/j.cell.2020.10.038  0.713
2020 Hatcher JM, Yang G, Wang L, Ficarro SB, Buhrlage S, Wu H, Marto JA, Treon SP, Gray NS. Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. Acs Medicinal Chemistry Letters. 11: 2238-2243. PMID 33214835 DOI: 10.1021/acsmedchemlett.0c00378  0.629
2020 Gray NS, Teng M, Jiang J, He Z, Kwiatkowski NP, Donovan KA, Mills CE, Victor C, Hatcher JM, Fischer ES, Sorger PK, Zhang T. Development of CDK2 and CDK5 Dual Degrader TMX-2172. Angewandte Chemie (International Ed. in English). PMID 32415712 DOI: 10.1002/Anie.202004087  0.806
2019 Zhang T, Hatcher JM, Teng M, Gray NS, Kostic M. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. Cell Chemical Biology. PMID 31631011 DOI: 10.1016/J.Chembiol.2019.09.012  0.783
2019 Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, et al. A kinase-independent role for CDK8 in BCR-ABL1 leukemia. Nature Communications. 10: 4741. PMID 31628323 DOI: 10.1038/S41467-019-12656-X  0.722
2019 Scott DA, Hatcher JM, Liu H, Fu M, Du G, Fontán L, Us I, Casalena G, Qiao Q, Wu H, Melnick A, Gray NS. Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Bioorganic & Medicinal Chemistry Letters. PMID 31129051 DOI: 10.1016/J.Bmcl.2019.05.040  0.765
2019 Hatcher JM, Du G, Fontán L, Us I, Qiao Q, Chennamadhavuni S, Shao J, Wu H, Melnick A, Gray NS, Scott DA. Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorganic & Medicinal Chemistry Letters. PMID 30954428 DOI: 10.1016/J.Bmcl.2019.03.046  0.777
2019 Wang L, Ferrao R, Li Q, Hatcher JM, Choi HG, Buhrlage SJ, Gray NS, Wu H. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). The Journal of Biological Chemistry. PMID 30679311 DOI: 10.1074/Jbc.Ra118.005428  0.625
2019 Fontan L, Hatcher J, Scott D, Qiao Q, Us I, Du G, Durant M, Wilson J, Wu H, Gray N, Melnick A. Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas Blood. 134: 2073-2073. DOI: 10.1182/Blood-2019-130666  0.804
2018 Fontán L, Qiao Q, Hatcher JM, Casalena G, Us I, Teater M, Durant M, Du G, Xia M, Bilchuk N, Chennamadhavuni S, Palladino G, Inghirami G, Philippar U, Wu H, et al. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. The Journal of Clinical Investigation. PMID 30024860 DOI: 10.1172/Jci99436  0.778
2018 Hatcher JM, Wang ES, Johannessen L, Kwiatkowski N, Sim T, Gray NS. Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8. Acs Medicinal Chemistry Letters. 9: 540-545. PMID 29937979 DOI: 10.1021/Acsmedchemlett.8B00011  0.783
2018 Hatcher JM, Wu G, Zeng C, Zhu J, Meng F, Patel S, Wang W, Ficarro SB, Leggett AL, Powell CE, Marto JA, Zhang K, Ki Ngo JC, Fu XD, Zhang T, et al. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chemical Biology. PMID 29478907 DOI: 10.1016/J.Chembiol.2018.01.013  0.78
2017 Wang L, Qiao Q, Ferrao R, Shen C, Hatcher JM, Buhrlage SJ, Gray NS, Wu H. Crystal structure of human IRAK1. Proceedings of the National Academy of Sciences of the United States of America. PMID 29208712 DOI: 10.1073/Pnas.1714386114  0.624
2017 Hatcher JM, Choi HG, Alessi DR, Gray NS. Small-Molecule Inhibitors of LRRK2. Advances in Neurobiology. 14: 241-264. PMID 28353288 DOI: 10.1007/978-3-319-49969-7_13  0.676
2017 Yang G, Hatcher J, Wang J, Liu X, Munshi M, Chen J, Xu L, Tsakmaklis N, Demos M, Kofides A, Chan G, Hunter Z, Patterson C, Gustine J, Castillo JJ, et al. A Novel, Highly Selective IRAK1 Inhibitor Jh-X-119-01 Shows Synergistic Tumor Cell Killing with Ibrutinib in MYD88 Mutated B-Cell Lymphoma Cells Blood. 130: 719-719. DOI: 10.1182/Blood.V130.Suppl_1.719.719  0.622
2017 Fontan L, Scott D, Hatcher J, Qiao Q, Us I, Casalena G, Bekkers M, Philippar U, Durant M, Chennamadhavuni S, Wu H, Gray N, Melnick A. Abstract LB-303: Substrate-mimetic covalent inhibitor of MALT1 is most effective against CARD11 mutant ABC-DLBCL Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-303  0.816
2016 Hatcher JM, Weisberg E, Sim T, Stone RM, Liu S, Griffin JD, Gray NS. Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. Acs Medicinal Chemistry Letters. 7: 476-81. PMID 27190596 DOI: 10.1021/Acsmedchemlett.5B00498  0.714
2015 Hatcher JM, Bahcall M, Choi HG, Gao Y, Sim T, George R, Janne PA, Gray NS. Discovery of inhibitors that overcome the G1202R ALK resistance mutation. Journal of Medicinal Chemistry. PMID 26568289 DOI: 10.1021/Acs.Jmedchem.5B01136  0.657
2015 Terai H, Tan L, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS, Hammerman PS. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. Acs Chemical Biology. PMID 26390252 DOI: 10.1021/Acschembio.5B00655  0.75
2015 Hatcher JM, Zhang J, Choi HG, Ito G, Alessi DR, Gray NS. Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor. Acs Medicinal Chemistry Letters. 6: 584-9. PMID 26005538 DOI: 10.1021/Acsmedchemlett.5B00064  0.731
2012 Choi HG, Zhang J, Deng X, Hatcher JM, Patricelli MP, Zhao Z, Alessi DR, Gray NS. Brain Penetrant LRRK2 Inhibitor. Acs Medicinal Chemistry Letters. 3: 658-662. PMID 23066449 DOI: 10.1021/Ml300123A  0.774
2011 Hatcher JM, Kohler MC, Coltart DM. Catalytic asymmetric addition of thiols to nitrosoalkenes leading to chiral non-racemic α-sulfenyl ketones. Organic Letters. 13: 3810-3. PMID 21714489 DOI: 10.1021/Ol2012633  0.719
2010 Hatcher JM, Coltart DM. Copper(I)-catalyzed addition of Grignard reagents to in situ-derived N-sulfonyl azoalkenes: an umpolung alkylation procedure applicable to the formation of up to three contiguous quaternary centers. Journal of the American Chemical Society. 132: 4546-7. PMID 20232808 DOI: 10.1021/Ja100932Q  0.638
Show low-probability matches.